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Abstract
A 72-year-old man was admitted to the hospital with fatigue. Colonoscopy revealed a 50 × 50 mm rectal tumor with bleed-
ing. Based on close inspection, he was diagnosed with unresectable advanced rectal cancer with multiple liver metastases. 
Chemotherapy was administered as 10 cycles of bevacizumab + mFOLFOX6 and 7 cycles of bevacizumab + FOLFIRI. Nine 
months later, he presented with hematochezia and progression of anemia. It was difficult to stop the bleeding via endoscopy. 
He underwent radiation therapy (39 Gy in 13 fractions), and hemostasis was confirmed. Then, further chemotherapy was 
performed with 3 cycles of bevacizumab + FOLFIRI and 2 cycles of TAS102. However 14 months after the initial visit, he 
presented with right hypochondralgia and abdominal fullness due to the progression of multiple liver metastases. Palliative 
low-dose whole-liver radiation therapy (WLRT) (30 Gy in 10 fractions) was performed. He developed Grade 2 nausea, but 
his right hypochondralgia reduced, liver dysfunction improved, and he successfully completed radiotherapy. At approxi-
mately the same time his anemia progressed, and colonoscopy revealed recurrent bleeding from the tumor. Re-irradiation 
(15 Gy in 5 fractions) of the rectal tumor was carried out and a blood transfusion was performed for the bleeding. He was 
discharged after confirmation the anemia had not progressed. Few reports have been published on the use of both palliative 
re-irradiation to stop bleeding from rectal cancer and palliative low-dose WLRT. Based on our experience with this case, 
we believe that palliative radiotherapy can be useful in treating patients with a poor prognosis.
Keywords Palliative radiotherapy · Low-dose whole-liver irradiation · Hemostasis re-irradiation
Introduction
Active bleeding sometimes occurs in unresectable rectal 
cancer, making it difficult to maintain hemostasis. Liver 
metastasis is one of the most common metastatic sites of 
unresectable rectal cancer [1]. Progression of liver metasta-
sis causes complications such as pain, fatigue, and liver dys-
function. We herein report a case of unresectable advanced 
rectal cancer with multiple liver metastases that was success-
fully treated with palliative radiotherapy.
Case report
A 72-year-old man was admitted to the hospital with fatigue 
that had lasted for several months. His medical history was 
15 years of diabetes mellitus and hypertension, both of 
which had been controlled with oral medications. He had no 
known allergic reactions to medications or foods. He did not 
smoke cigarettes, and he drank alcohol only occasionally.
Lower gastrointestinal endoscopy showed a 50 × 50 mm 
infiltrative ulcerative type rectal cancer located 15 cm from 
the pectinate line of the anal canal (Fig. 1a). Mild stenosis 
was found around the tumor, but a scope could pass through 
the stenosis. An abdominal contrast-enhanced computed 
tomography (CT) scan revealed numerous metastases in 
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both lobes of the liver (Fig. 1b). Parameters for the CT were 
as follows: 2 mm slice thickness, 50 × 50 cm field of view, 
and settings of 150 mA and 120 kV (16-row multidetector 
CT; Alexion, Toshiba Medical System; Otawara, Japan). 
He was diagnosed with unresectable advanced rectal cancer 
with multiple liver metastases. Chemotherapy was admin-
istered with 10 cycles of bevacizumab + mFOLFOX6 and 
7 cycles of bevacizumab + FOLFIRI. Nine months after 
the initial admission, he presented with hematochezia and 
progression of anemia. It was difficult to stop the bleeding 
via endoscopy, so six units of blood transfusion were per-
formed. He underwent radiation therapy (39 Gy in 13 frac-
tions) (Elekta Synergy System, Elekta Ltd, Crawley, UK). 
Hemostasis was successfully confirmed (Fig. 2a–c). Then, 
further chemotherapy was performed with 3 cycles of beva-
cizumab + FOLFIRI and 2 cycles of TAS102.
However, 13 months after the initial visit, he presented 
with right hypochondrial pain and abdominal fullness. 
Abdominal diffusion-weighted magnetic resonance imaging 
(MRI) showed the progression of multiple liver metastases. 
Parameters for the MRI were as follows: gradient echo; TR/
TE in ms: 1200/70; NSA: 5; matrix: 80 × 256; and B value: 
1000 (MRI, Achieva; Philips Medical Systems, Best, the 
Netherlands). These metastatic lesions oppressed hepatic 
capsulitis (Fig. 3a). His prognosis was thought to be only a 
few months, and he wanted to remain at his home for the end 
of his life. Despite the use of an adequate dosage of opioid 
analgesics, his hypochondrial pain did not improve. This 
prevented him from being discharged from the hospital. At 
that time, his liver function was Child–Pugh Class B (no 
encephalopathy, no ascites, total bilirubin level: 2.7 mg/dL, 
albumin level: 2.3 g/dL, PT activity: 91.8%). After thorough 
discussion of treatment options with the patient, informed 
consent was given to perform palliative low-dose whole-liver 
radiation therapy (WLRT) (Fig. 3b). The dose of WLRT 
administered was 30 Gy in 10 fractions. The coverage of 
95% of planned treatment volume was 30 Gy. He developed 
Grade 2 nausea, but his right hypochondrial pain reduced 
and the liver dysfunction was improved (total bilirubin: 
2.7 → 1.2 mg/dL, aspartate aminotransferase: 53 → 35 IU/L, 
alanine aminotransferase: 10 → 13 IU/L, lactate dehydroge-
nase: 1813 → 863 IU/L). Thus, he successfully completed 
radiotherapy. Seven days after the palliative WLRT, his ane-
mia progressed. Lower gastrointestinal endoscopy revealed 
recurrent bleeding from the tumor. It was difficult to com-
pletely stop the bleeding via endoscopy, so eight units of 
blood were transfused. Five months after the initial RT, the 
rectal cancer was re-irradiated. The prescribed dose was 
15 Gy in 5 fractions (Fig. 4). He wished to return home as 
soon as possible, so we had to plan a short treatment course. 
On the 28th hospital day, he was discharged after confirma-
tion that the anemia had not progressed. He succumbed to 
the disease after 7 weeks of re-irradiation (Fig. 5). During 
this period, he was free from right hypochondrial pain and 
abdominal fullness and there was no recurrence of bleeding 
from the tumor.
Discussion
Bleeding from unresectable digestive cancer sometimes 
reduces a patient’s quality of life. There are many ways to 
stop bleeding from digestive cancer including endoscopic 
hemostasis, surgery, and vascular embolization. A number 
of reports have been published about palliative hemostatic 
irradiation for digestive cancer, but there have been no Phase 
III studies on this; the dose fractionation also remains con-
troversial. Furthermore, only one case report could be found 
on the topic of palliative re-irradiation for gastric cancer 
with bleeding [2] and no mass study has been conducted 
about palliative re-irradiation for colon cancer.
Our first prescribed dose was relatively higher (39 Gy 
in 13 fractions) than that typically used for hemostasis 
Fig. 1  a Lower colonal endoscopic examination revealed the infiltra-
tive ulcerative-type rectal cancer located 15 cm distance from pecti-
nate line of anal canal. b Abdominal contrast computed tomography 
(late phase) revealed numerous metastases in both lobes of the liver
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radiotherapy for gastric cancer (20–30 Gy) [3–5]. The radio-
therapy administered was based on the previous studies [6]. 
The radiation dose may be reduced when used for treatment 
of gastric cancer. However, in this case, frequent blood trans-
fusions were needed before the first palliative irradiation, 
and it was difficult for the patient to return to our hospital 
frequently because he lived far away. Hence, our treatment 
plan was to increase the dosage as much as possible within 
safe limits.
On the other hand, there are not many studies about pal-
liative WLRT for relief of right hypochondrial pain or sensa-
tions of fullness, and there is no consensus about safe dose 
fractionation or duration to prevent radiation induced hepa-
titis. To the best of our knowledge, there are 9 studies about 
low-dose palliative radiotherapy alone for liver metastases 
(Table 1: [7–15]) (searching on the PubMed, from 1954 
to 2018). In these studies, patients received WLRT with 
1.5–8 Gy fractions per day up to 8–37.5 Gy. Median sur-
vival was 10–20 weeks among the 5 traceable studies. The 
analysis of the primary site in the 9 previous studies revealed 
that most of the primary sites were the colon and rectum, fol-
lowed by the stomach, lung, and pancreas (Fig. 6). Only one 
study of palliative WLRT compared its efficacy and compli-
cations in hepatocellular carcinoma (HCC) with liver metas-
tases [14] and reported no significant differences between 
the two categories. Hoyer et al. recommended 2 Gy fractions 
of up to 30–35 Gy for palliative WLRT in a 2012 critical 
review [16]. To summarize the previous studies of WLRT, 
the appropriate population and advantage or disadvantage of 
palliative WLRT are as follows: the appropriate population 
are patients with symptoms (pain, abdominal discomfort, 
etc.) of liver metastasis or HCC. The advantage or main 
target of palliative WLRT is to improve the quality of life of 
patients by reducing the compression symptom and improv-
ing liver dysfunction caused by the occlusion of the intrahe-
patic bile duct. The disadvantage of this therapy is the same 
as the general complication of irradiation. In addition, an 
irradiation dose greater than the liver tolerance level confers 
a risk of acute hepatic insufficiency.
In this case, we chose 30 Gy in 10 fractions based on 
the literature to avoid radiation-induced hepatitis. The 
patient’s right hypochondrial pain and sense of abdominal 
distension was improved. In the case of multiple metas-
tases in the liver spreading to whole liver and causing 
liver dysfunction, we cannot expect a long-term progno-
sis. For this reason, we prioritized symptomatic improve-
ment using short-term radiotherapy and gave less con-
sideration to the delayed toxicity. This was the rationale 
for the 10-day radiation this time, so we administered 
30 Gy in 10 fractions. The liver dysfunction improved and 
radiation-induced hepatitis did not develop. We did not 
measure the pain scale score this time, but the patient’s 
complaints of abdominal pain disappeared. Re-irradiation 
to the rectal cancer was carried out with 15 Gy in 5 frac-
tions. The rationale for this dose fraction was as follows: 
first of all, we had already reported successful salvage 
of hemostasis via twice radiotherapy for gastric cancer 
(the salvage dose was 15 Gy) [17–19]. The patients did 
Fig. 2  a Lower colonal endo-
scopic examination when he 
presented with hematochezia 
(before hemostasis radiother-
apy). b Abdominal computed 
tomography. Orange area is 
the target zone of hemostasis 
radiotherapy. Pink line shows 
outer wall of rectal cancer 
(Gross target volume). The red 
color zone indicates 100% of 
prescribed dose (39 Gy). The 
green color zone indicates 95% 
of prescribed dose. The blue 
color zone indicates 50% of pre-
scribed dose. c Sagittal image of 
abdominal computed tomogra-
phy before first irradiation to the 
rectal cancer. d Lower colonal 
endoscopic examination that 
was performed 1 month after 
hemostasis radiotherapy
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not develop Grade 2 or worse adverse events. Hemostasis 
re-irradiation was carried out based on those reports. The 
tolerable doses of the rectum and colon are different. In 
general, the rectum and colon can tolerate up to 60 and 
45 Gy, respectively [20]. In this case, the total dose was 
54 Gy, so for the surrounding colon, the total dose seems 
high. However, the rectum is difficult to irradiate while 
partially avoiding the colon, because the rectal cancer is 
located in the pelvis.
Second of all, we had to plan a short treatment period 
because the prognosis was poor and he wished to return 
home as soon as possible. No complication developed and 
he was able to spend his remaining time at home without 
any episode of gastrointestinal bleeding. He passed away 
7 weeks after discharge due to deterioration of his general 
condition.
Conclusion
This case of unresectable advanced rectal cancer with liver 
metastases was successfully treated with re-irradiation to the 
rectal cancer and palliative low-dose whole-liver radiation 
therapy. We believe that palliative radiotherapy can be useful 
for patients with a poor prognosis.
Fig. 3  a Abdominal diffusion-weighted magnetic resonance imag-
ing showed the progression of multiple liver metastases. b Abdomi-
nal computed tomography of the target zone of palliative low-dose 
whole-liver radiation therapy. Gross target volume is the whole liver. 
The yellow color zone indicates 100% of prescribed dose (30  Gy). 
The light blue color zone indicates 95% of prescribed dose. The blue 
color zone indicates 50% of prescribed dose
Fig. 4  Sagittal image of abdominal computed tomography before re-
irradiation to the rectal cancer
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